Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

653789.pdf (670.78 KB)

Document type

Article

Version

Published version

Publication date

2014-11-14

Publication license

cc-by (c) Matas, Elisabet et al., 2014
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/123875

Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1371/journal.pone.0112758

Abstract

Background Myxovirus resistance protein A (MxA) is a molecule induced after interferon-beta injection, mostly used to evaluate its bioactivity. There is little available data on clinical utility of baseline MxA mRNA status. The objective of the study is to investigate whether baseline MxA mRNA expression can predict relapse and disease progression in multiple sclerosis patients treated with interferon-beta. Methods Baseline blood samples were obtained before the first interferon-beta dose was administered to evaluate MxA mRNA expression using real-time polymerase chain reaction (PCR). Demographic and clinical variables were prospectively recorded to define treatment responder and non responder groups. Results 104 patients were included in the study. Baseline MxA mRNA expression was significantly lower in the group of patients who met the definition of responders (1.07 vs 1.95, Student t test, p<0.0001). A threshold of 1.096 was established using Receiver Operating Characteristic analysis to differentiate between responders and non-responders (sensitivity 73.9%, specificity 69.0%). Survival analysis using this threshold showed that time to next relapse (p<0.0001) and to EDSS progression (p = 0.01) were significantly higher in patients with lower MxA titers. Conclusion The results suggest that baseline MxA mRNA levels may be useful for predicting whether multiple sclerosis patients will respond or not to interferon-beta treatment.

Subject

Immunologia, Esclerosi múltiple

Subject (English)

Immunology, Multiple sclerosis

Citation

Collections

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

MATAS MARTÍN, Elisabet, et al. Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PLoS One. 2014. Vol. 9, num. 11, pags. 1-6. ISSN 1932-6203. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/123875

Export metadata

JSON - METS

Share record